Sanofi Ends Lung Cancer Drug Study After Trial Failure (1)

Sanofi will stop developing an experimental lung cancer medicine after it failed to impress in a late-stage trial.

The French drugmaker is terminating the program for tusamitamab ravtansine, an antibody-based treatment that failed to outperform a chemotherapy in treating some patients with metastatic non-squamous non-small cell lung cancer.

Sanofi shares fell as much as 1.7% in Paris. The stock is down nearly 12% since Sanofi surprised investors in October with a forecast for lower profit next year, which overshadowed optimism about a plan to spin off the consumer health division.

While the decision is a setback to Sanofi’s pipeline of ...